The health ministry on Tuesday officially authorized the use of U.S. biopharmaceutical firm Novavax Inc.’s COVID-19 vaccine, making it the fourth coronavirus vaccine available in Japan.
The Novavax vaccine is a recombinant protein vaccine, unlike the three vaccines already approved. According to the ministry, the vaccine is effective against the highly infectious omicron variant of the coronavirus, albeit less so compared with other variants.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.